

H K E C L E H K L
 C C C C C C C C C C C C
 C C C C C C C C C C C C
 C C C C C C C C C C C C



上海復星醫藥（集團）股份有限公司
 Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

(C C C C C C)
 (Stock Code: 02196)

2013 THIRD QUARTERLY REPORT

TS R 13.09(2) R 13.10B f R s G r t
 L f S r s T S E f H K L f I f r
 P s s r Pr I A f S r s F r s O (C r 571 f L s f H K r).

T f i s t f r r r r r f r 2013 f S μ F s P r (G) C .
 L . * (“Company”, f r b s s b r s s “Group”). T f r r
 f r s r r r r r b PRC A S f r B s s s E r r s s f s
 b

B O r f B r
 Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*
 Chen Qiyu
 C C

S μ f P s' R b f C
 30 O b r 2013

A C F ;
 G G C C C G C C C C C K L C C
 C H C H C J D L C A C D C

* F C C C

After the reporting period ends:

Unit: RMB

Items	The Reporting Period (Jul - Sep)	From the beginning of the year to the end of the Reporting Period	Description
Gross fixed assets	10,251,236.77	596,825,644.44	
Gross fixed assets less accumulated depreciation and impairment loss	2,878,850.90	13,168,079.40	
Gross fixed assets less accumulated depreciation and impairment loss less net deferred income tax assets			

§3 SIGNIFICANT EVENTS

3.1 Significant events during the reporting period

A N/A

Currency: RMB

Balance Sheet				
Items	Closing balance as at the end of the Period	Opening balance as at the beginning of the Year	Ratio of change	Reasons
Capital	2,485,783,000.50	4,972,524,758.70	-50%	Decrease in capital due to the distribution of dividends in 2013.
Prepaid expenses	1,316,781,579.78	907,307,576.06	45%	Increase in prepaid expenses due to the increase in prepayments for advertising and other expenses in 2013.
Inventory	7,615,057.77	17,674,707.55	-57%	Decrease in inventory due to the decrease in inventory levels in 2013.
Intangible assets	2,368,367,750.12	1,752,799,860.87	35%	Increase in intangible assets due to the acquisition of intangible assets in 2013.
Development expenses	42,946,124.18	29,475,413.33	46%	Increase in development expenses due to the increase in R&D expenses in 2013.
Goodwill	2,710,407,586.05	1,661,770,763.96	63%	Increase in goodwill due to the acquisition of goodwill in 2013.
Other non-current assets	236,069,350.21	100,654,101.39	135%	Increase in other non-current assets due to the increase in other non-current assets in 2013.
Deferred tax assets	72,033,067.63	31,482,514.80	129%	Increase in deferred tax assets due to the increase in deferred tax assets in 2013.
Shareholders' equity	1,199,559,074.08	519,422,250.00	131%	Increase in shareholders' equity due to the increase in shareholders' equity in 2013.
Debt	12,240,519.57	4,725,748.28	159%	Increase in debt due to the increase in debt in 2013.
Other current liabilities	33,196,473.53	526,384,431.15	-94%	Decrease in other current liabilities due to the decrease in other current liabilities in 2013.

Income Statement				
Items	From the beginning of the year to the end of the Reporting Period	From the beginning of the previous year to the end of the Reporting Period of the previous year	Ratio of change	Reasons
	(Jan – Sep)	(Jan – Sep)		
Operating Profit	7,070,780,938.31	5,387,845,935.96	31%	Mainly due to the increase in sales volume and the decrease in operating expenses compared with the same period of 2013.
Operating Loss	3,957,631,876.59	3,005,217,397.09	32%	Mainly due to the increase in sales volume and the decrease in operating expenses compared with the same period of 2013.
Gain from disposal of assets ("–" represents loss)	39,511,717.28	-14,636,854.56	N/A	Mainly due to the increase in the gain from disposal of assets compared with the same period of 2013.
Income before taxes	313,206,671.22	202,061,631.73	55%	Mainly due to the increase in sales volume and the decrease in operating expenses compared with the same period of 2013.
Net Profit	72,257,721.95	33,558,889.22	115%	Mainly due to the increase in sales volume and the decrease in operating expenses compared with the same period of 2013.
Other comprehensive income	285,252,496.15	-436,322,994.17	N/A	Mainly due to the increase in other comprehensive income compared with the same period of 2013.

Statement of Cash Flow				
Items	From the beginning of the year to the end of the Reporting Period	From the beginning of the previous year to the end of the Reporting Period of the previous year	Ratio of change	Reasons
	(Jan – Sep)	(Jan – Sep)		
Net cash flow	-1,757,461,995.58	-368,977,652.38	376%	Mainly due to the increase in cash flow compared with the same period of 2013.

3.2 A. s.s. ... f r r s s s f j r s .

√ A b □ N b

O. 26 S b r 2013 f f f (r r r) f s f s s s f B r t 2013 f (r r r) f s f s s s f S r s r C t s r r t r s f R s r p S r I \$ (r f) f p S μ F s p r (G) C , L * O 25 O b r 2013 f C S R C s s r f b f r f “ O t t p S μ F s p r (G) C , L R s r A p S r I \$ ” (S i p S B H 2013 N 774) A r t f b f f C S R C t B r r s t r s t r f r r t R s r p S r I \$ (s r f) f p S μ F s p r (G) C , L * b s t s f f C t t t (r r) f s f s s s f B r t 2013 f t (r r r) f s f s s s f

上海医药集团股份有限公司
（股票代码：600829）
上海医药集团股份有限公司
（股票代码：600829）

3.3 凡在本公司...

A B N A B

3.4 / ...

A B N A B

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

Li ... : Chen Qiyu

30 Oct 2013

Consolidated balance sheet (Continued)

30

2013

Items	Closing balance as at the end of the Period	Opening balance as at the beginning of the Year
Equity attributable to the owners (or equity attributable to shareholders):		
Paid-up capital (including share premium)	2,240,462,364.00	2,240,462,364.00
Reserves	4,396,998,107.25	4,287,287,930.01
Less: Reserves		
Shareholders' equity		
Shareholders' equity	1,338,476,598.49	1,338,476,598.49
Government grants		
Government grants	6,621,610,997.36	5,703,028,462.15
Financial instruments at fair value	-4,289,492.31	-10,462,767.38
Trade receivables	14,593,258,574.79	13,558,792,587.27
Trade payables	1,889,445,595.04	1,745,855,848.86
Trade receivables	16,482,704,169.83	15,304,648,436.13
Trade payables	27,589,580,696.34	25,507,140,466.01

Liabilities

Current liabilities

Debt

Balance sheet of the Parent Company

30

2013

Parent: Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

Currency: RMB Tenthousand:

Items	Closing balance as at the end of the Period	Opening balance as at the beginning of the Year
Current Assets:		
Cash and cash equivalents	967,810,425.06	2,804,108,583.37
Financial assets at fair value		
Derivatives		
Receivables		
Prepaid expenses		
Inventory	112,185,785.22	98,972,778.68
Due from related parties	24,240,000.00	
Other receivables	1,207,151,982.57	941,562,545.17
Intangible assets	517,042.01	516,409.53
Non-current financial assets		
Other non-current assets	280,000,000.00	250,000,000.00
Total current assets	2,591,905,234.86	4,095,160,316.75
Non-current assets:		
Available-for-sale financial assets		
Long-term equity investments		
Long-term debt investments	5,471,340,934.74	4,173,763,622.82
Intangible assets		
Fixed assets	20,153,012.47	20,815,349.96
Construction in progress		
Right-of-use assets		
Deferred tax assets		
Other non-current assets		
Intangible assets	3,215,662.67	3,496,198.41
Deferred tax assets		
Goodwill		
Long-term equity investments		
Deferred tax assets		
Other non-current assets	4,470,831,299.40	4,035,133,683.09
Total non-current assets	9,965,540,909.28	8,233,208,854.28
Total assets	12,557,446,144.14	12,328,369,171.03

Balance sheet of the Parent Company (Continued)

30

2013

Items	Closing balance as at the end of the Period	Opening balance as at the beginning of the Year
Current liabilities:		
Short-term debt		
Accounts payable		
Accrued liabilities		
Income taxes payable		
Other current liabilities		
Total	26,138,331.81	29,108,232.08
Long-term debt		
Accounts payable		
Accrued liabilities		
Income taxes payable		
Other non-current liabilities		
Total	16,833,088.84	5,188,721.77
Long-term debt		
Accounts payable		
Accrued liabilities		
Income taxes payable		
Other non-current liabilities		
Total	155,509,208.37	152,405,396.96
Deferred income taxes		
Other non-current liabilities		
Total	554,584,851.12	46,800,203.98
Accounts payable		
Accrued liabilities		
Income taxes payable		
Other non-current liabilities		
Total	360,000,000.00	355,000,000.00
Accounts payable		
Accrued liabilities		
Income taxes payable		
Other non-current liabilities		
Total	1,113,065,480.14	1,087,877,554.79
Non-current liabilities:		
Long-term debt	125,000,000.00	165,000,000.00
Accounts payable	4,070,832,033.25	4,063,347,254.54
Long-term debt		
Accounts payable		
Accrued liabilities		
Income taxes payable		
Other non-current liabilities		
Total	2,275,000.00	2,500,000.00
Accounts payable		
Accrued liabilities		
Income taxes payable		
Other non-current liabilities		
Total	4,198,107,033.25	4,230,847,254.54
Accounts payable		
Accrued liabilities		
Income taxes payable		
Other non-current liabilities		
Total	5,311,172,513.39	5,318,724,809.33
Equity attributable to the owners (or equity attributable to shareholders):		
Preferred stock	2,240,462,364.00	2,240,462,364.00
Common stock	3,754,014,307.53	3,755,009,519.04
Retained earnings		
Accumulated other comprehensive income		
Share-based compensation	305,635,420.68	305,635,420.68
Goodwill		
Other non-current assets	946,161,538.54	708,537,057.98
Total	7,246,273,630.75	7,009,644,361.70
Total	12,557,446,144.14	12,328,369,171.03

Liabilities

Current liabilities

Debt

Consolidated Income Statement

J € — 2013

Parent: Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

Items	Current Amount (Jul – Sep)	Amount of the Last Period (Jul – Sep)	From the beginning of the year to the end of the Reporting Period (Jan – Sep)	From the beginning of the previous year to the end of the Reporting Period of the previous year (Jan – Sep)
I. Total	2,561,491,585.94	1,893,571,781.13	7,070,780,938.31	5,387,845,935.96
Income: Operating	2,561,491,585.94	1,893,571,781.13	7,070,780,938.31	5,387,845,935.96
Income				
Expenses				
Finance				
II. Total	2,386,286,775.10	1,788,349,054.26	6,624,840,911.15	5,169,344,744.07
Income: Operating	1,443,380,576.18	1,070,386,676.04	3,957,631,876.59	3,005,217,397.09
Income				
Finance				
Profit				
Cost				
Non-operating				
Profit				
Assets				
Basic	17,703,464.04	15,513,271.83	53,354,062.65	45,680,204.73
Share	479,445,326.56	378,562,373.30	1,365,131,254.39	1,095,194,687.55
Assets	348,227,860.44	233,150,221.33	953,270,651.18	737,364,358.43
Finance	96,141,071.35	89,160,189.77	284,390,085.53	276,468,676.31
Assets	1,388,476.53	1,576,321.99	11,062,980.81	9,419,419.96
Profit: Gross Profit	-548,949.75	-4,627,534.57	39,511,717.28	-14,636,854.56
Income	290,003,715.25	421,463,463.75	1,383,399,844.53	1,287,581,764.07
Income: Gross Profit	201,434,469.70	198,347,616.50	581,668,523.72	576,814,622.40
Profit				
III. Operating	464,659,576.34	522,058,656.05	1,868,851,588.97	1,491,446,101.40
Profit: Non-operating	19,388,740.32	10,990,516.89	72,257,721.95	33,558,889.22
Loss: Non-operating	1,260,832.39	1,998,060.21	7,231,879.03	6,724,472.72
Income: Loss	260,198.27	-243,201.72	979,886.77	946,040.98

Income Statement of the Parent Company

July 2013

Parent Company: Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

Currency: RMB Tenthousand Yuan

Items	Current Amount (Jul - Sep)	Amount of the Last Period (Jul - Sep)	From the beginning of the year to the end of the Reporting Period (Jan - Sep)	From the beginning of the previous year to the end of the Reporting Period of the previous year (Jan - Sep)
I. Operating Income				
Less: Operating Expenses				
Business Expenses				
Salaries				
Administrative Expenses	25,499,951.01	17,552,163.07	82,756,689.01	80,257,596.41
Financial Expenses	17,330,429.70	20,109,120.09	27,772,618.27	53,461,091.55
Assets Impairment Losses				
Provision for Doubtful Accounts				
Income Tax Expenses ("-" indicates income tax credit)	8,229,013.36	242,785,000.00	820,929,379.59	459,475,631.89
Income from Government Grants	6,268,813.36	2,665,000.00	1,839,063.36	27,355,631.89
II. Operating Profit ("-" indicates loss)	-34,601,367.35	205,123,716.84	710,400,072.31	325,756,943.93
Plus: Non-Operating Income	76,900.00	234,093.38	236,049.11	734,093.38
Less: Non-Operating Expenses		-570,000.00	2,514,544.42	860,000.00
Income from Disposal of Long-Term Assets			5,725.77	
III. Total Profit ("-" indicates loss)	-34,524,467.35	205,927,810.22	708,121,577.00	325,631,037.31
Less: Income Tax				
IV. Net Profit ("-" indicates loss)	-34,524,467.35	205,927,810.22	708,121,577.00	325,631,037.31
Minority Interests				
(1) Minority Interests				
(2) Minority Interests				
I. Operating Profit			51,779.40	27,699,470.25
II. Total Profit	-34,524,467.35	205,927,810.22	708,173,356.40	353,330,507.56

Li Rui, Chief Financial Officer
 Chen Qian, Director
 Huifeng Jiang, Director
 Dong Jie, Director

Consolidated Statement of Cash Flow (Continued)

J G -

2013

Items	From the beginning of the year to the end of the Reporting Period (Jan - Sep)	From the beginning of the previous year to the end of the Reporting Period of the previous year (Jan - Sep)
II. Cash flow generated from investing activities (Continued):		
Cash for sale of investments	711,664,658.89	839,693,736.40
Cash for sale of property, plant and equipment	251,949,461.45	734,761,521.45
Net sales of investments		
Net cash for sale of investments	2,011,879,515.78	
Proceeds from sale of investments	100,020,349.23	9,072,797.31
Subsidy for investment	3,075,513,985.35	1,583,528,055.16
Net cash for investment	-1,757,461,995.58	-368,977,652.38
III. Cash flow generated from financing activities:		
Cash for interest	2,088,710.98	761,199.00
Interest for business development	2,088,710.98	761,199.00
Cash for interest	1,302,361,982.24	1,022,152,808.76
Cash for interest		1,486,950,000.00
Proceeds from sale of investments	329,448,475.13	262,541,891.46
Subsidy for investment	1,633,899,168.35	2,772,405,899.22
Cash for interest	1,221,891,677.53	2,628,044,486.20
Cash for interest	950,844,046.86	601,916,917.03
Interest for business development	702,264,204.84	366,813,171.49
Proceeds from sale of investments	48,488,630.70	101,408,014.93
Subsidy for investment	2,221,224,355.09	3,331,369,418.16
Net cash for investment	-587,325,186.74	-558,963,518.94
IV. Effects of exchange rate fluctuations on cash and cash equivalents	-25,426,268.76	-4,569,909.53
V. Net increase of cash and cash equivalents	-1,902,809,425.34	-517,020,589.16
Periodic interest	4,171,574,742.12	2,428,219,484.36
VI. Closing balance of cash and cash equivalents	2,268,765,316.78	1,911,198,895.20

L. R. s. f. C. Q.

C. f. F. Off. r. H. i. f. J.

D. r. f. A. J.

Statement of Cash Flow of the Parent Company (Continued)

J 6 -

2013

Items	From the beginning of the year to the end of the Reporting Period (Jan - Sep)	From the beginning of the previous year to the end of the Reporting Period of the previous year (Jan - Sep)
III. Cash flow generated from financing activities:		
Cash flow from operations		
Cash flow from investments	255,115,078.77	
Cash flow from financing		1,486,950,000.00
Operating activities	1,904,031,173.98	4,295,169,165.49
Subsidiary financing	2,159,146,252.75	5,782,119,165.49
Cash flow from operations	790,115,078.77	454,000,000.00
Cash flow from operations	674,744,025.09	302,177,196.32
Operating activities	2,109,471,293.35	5,478,222,986.00
Subsidiary financing	3,574,330,397.21	6,234,400,182.32
Net financing	-1,415,184,144.46	-452,281,016.83
IV. Effects of exchange rate fluctuations on cash and cash equivalents	-22,851,531.32	
V. Net increase of cash and cash equivalents	-1,198,160,658.31	-9,857,758.83
Operating activities	2,090,971,083.37	155,005,881.32
VI. Closing balance of cash and cash equivalents	892,810,425.06	145,148,122.49

L i R r s f
C : C Q .

C f F Off . r :
H . i f J .

D r f A
D . r : J .